Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Jun;60(6):1001-8.
doi: 10.1002/pbc.24435. Epub 2012 Dec 19.

Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomas

Douglas S Hawkins  1 , Sheri L Spunt, Stephen X Skapek; COG Soft Tissue Sarcoma Committee
Affiliations
Review

Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomas

Douglas S Hawkins et al. Pediatr Blood Cancer. 2013 Jun.

Abstract

In the US, approximately 850-900 children are diagnosed each year with soft tissue sarcomas (STS). Key findings from recent Children's Oncology Group (COG) clinical trials include safe reduction in therapy for low risk rhabdomyosarcoma (RMS), validation of FOXO1 fusion as a prognostic factor, a modest improvement in outcome for high-risk RMS, and a biologically designed non-cytotoxic therapy for pediatric desmoid tumor. Planned Phase 2 trials include targeted agents for VEGF/PDGF, mTOR, and IGF-1R for children with RMS and VEGF for children with non-RMS STS (NRSTS). For RMS, COG Phase 3 trials potentially will explore VEGF/mTOR inhibition or chemotherapy interval compression. For NRSTS, a COG Phase 3 trial will explore VEGF inhibition.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interests to report related to this manuscript or the activities described.

References

    1. Li J, et al. Cancer incidence among children and adolescents in the united states, 2001-2003. Pediatrics. 2008 - PubMed
    1. Gurney JG, et al. In: Soft Tissue Sarcomas in Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. LAG Ries, et al., editors. Bethesda: National Cancer Institute, SEER Program; 1999.
    1. Sultan I, Qaddoumi I, Yaser S, Rodriguez-Galindo C, Ferrari A. Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: an analysis of 2,600 patients. J Clin Oncol. 2009 Juld;27(20):3391–7. - PubMed
    1. Malempati S, Hawkins DS. Rhabdomyosarcoma: review of the Children's Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies. Pediatr Blood Cancer. 2012 Jul 15;59(1):5–10. - PMC - PubMed
    1. Meza JL, Anderson J, Pappo AS, Meyer WH. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group. J Clin Oncol. 2006 Aug 20;24(24):3844–51. - PubMed

Substances